Technology Prognosis

tracking technologies before you have to make a decision

Prognosis is a horizon scanning service that monitors emerging health technologies as they go through clinical trial development and the regulatory approval process.

View a sampling of our Prognosis reports.

Tisagenlecleucel-T (CTL019)

March 23, 2017 Technology Prognosis

Tisagenlecleucel-T is an autologous chimeric antigen receptor (CAR) T-cell therapy that targets the CD19 surface antigen expressed in aggressive B cell malignancies. It is produced by adapting the patient’s own immune cells with tumor antigen recognition and T-cell activation domains. The process of producing tisagenlecleucel-T begins with collecting peripheral blood mononuclear cells from the patient via leukapheresis. These cells are then sent to a laboratory or a pharmaceutical manufacturing facility where they are genetically engineered to produce CARs on their surface. These reengineered T cells, known as CAR T cells, are able to recognize an antigen on targeted tumor cells....

Binimetinib for NRAS-Mutated Melanoma

March 21, 2017 Technology Prognosis

Binimetinib is an investigational, oral small-molecule targeting the mitogen-activated protein kinase (MAPK) pathway. Mitogen-activated protein kinase enzyme (MEK) is a key protein kinase in the MAPK pathway, which regulates several key cellular activities, including proliferation, differentiation, migration, survival, and angiogenesis. Inappropriate activation of this pathway has been shown to occur in many cancers.  This report addresses the use of binimetinib in NRAS-mutated melanoma; it is also in development for BRAF-mutated melanoma.

Kisqali (Ribociclib)

March 16, 2017 Technology Prognosis

Kisqali is an oral cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitor. CDK 4/6 are commonly overexpressed in breast cancer tumors, and increased CDK 4/6 activity is associated with resistance to hormone therapy. Kisqali is intended for use in combination with letrozole (brand name Femara; Novartis), an aromatase inhibitor commonly prescribed for first-line hormone therapy in women with HR+/HER2– breast cancer.

Abaloparatide (BA058)

March 15, 2017 Technology Prognosis

Abaloparatide is an investigational synthetic peptide analog of parathyroid hormone-related protein (PTHrP) that is proposed for the treatment of osteoporosis in postmenopausal women.  It is an anabolic agent that is self-administered once daily by subcutaneous (SC) injection.

Cobra PzF NanoCoated Coronary Stent

March 9, 2017 Technology Prognosis

The Cobra PzF stent is a first-in-class nanocoated coronary stent that is FDA-approved for improving coronary luminal diameter in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions in native coronary arteries. The Cobra PzF stent utilizes a proprietary Polyzene-F nanothin polymer coating on a thin strut, open cell cobalt chromium stent platform. The Cobra PzF stent is not a drug eluting stent.   The Polyzene-F nanocoating is a proprietary, ultra-thin, durable and elastic polymer that is designed to be highly biocompatible and act as a barrier between the stent metal, blood and circulating...